In an efficacy analysis that included patients who received free-base rociletinib at a dose of @ mg twice daily or the HBr form at any dose , the objective response rate among the @ patients with T@M-positive disease who could be evaluated was @ % ( @ % confidence interval -LSB- CI -RSB- , @ to @ ) , and the rate among the @ patients with T@M-negative disease who could be evaluated was @ % ( @ % CI , @ to @ ) .